Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | TK2 | O00142 | 5/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brivudine SCHEMBL13030272 | 1.00 | TK1 (1.00) | TK1CYP1A2CYP3A4TSHRBLM | |
| Brivudine SCHEMBL4283383 | 1.00 | TK1 (1.00) | TK1CYP1A2CYP3A4TSHRBLM | |
| Brivudine SCHEMBL4314668 | 1.00 | TK1 (1.00) | TK1CYP1A2CYP3A4TSHRBLM | |
| Brivudine SCHEMBL141407 | 1.00 | TK1 (1.00) | TK1CYP1A2CYP3A4TSHRBLM | |
| Brivudine SCHEMBL13674189 | 1.00 | TK1 (1.00) | TK1CYP1A2CYP3A4TSHRBLM | |
| Brivudine SCHEMBL1172398 | 1.00 | TK1 (1.00) | TK1CYP1A2CYP3A4TSHRBLM | |
| Brivudine SCHEMBL4283382 | 1.00 | TK1 (1.00) | TK1CYP1A2CYP3A4TSHRBLM | |
| Brivudine SCHEMBL5983819 | 1.00 | TK1 (1.00) | TK1CYP1A2CYP3A4TSHRBLM | |
| Brivudine SCHEMBL21316784 | 1.00 | TK1 (1.00) | TK1CYP1A2CYP3A4TSHRBLM | |
| Brivudine SCHEMBL15405329 | 1.00 | TK1 (1.00) | TK1CYP1A2CYP3A4TSHRBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5066 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| WO-2026107113-A1 | MODIFIED CELLS FOR PROGRAMMING EXTRA ENVELOPED VIRUSES (EEVs) AND THEIR USE FOR PRODUCING THE EEVs, THE PROGRAMMED EEVs AND USES THEREOF | CALIDI BIOTHERAPEUTICS (NEVADA), INC. (US) | 2026-05-21 | — | — | WO | claimed |
| CN-122056884-A | Methods of treating pancreatic cancer | 坎莫森特里克斯公司 | 2026-05-19 | — | — | CN | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-3790536-B1 | NANOCONTAINERS FOR TRANSPORTING NONPOLAR, LIPOPHILIC SUBSTANCES SUCH AS ANTIBIOTICS | KARLSRUHER INST TECHNOLOGIE (DE) | 2026-04-22 | — | — | EP | claimed |
| US-12599644-B2 | Treatment of coronavirus infection with Flt3 receptor interacting lectin (FRIL) | ACADEMIA SINICA (TW) | 2026-04-14 | — | — | US | claimed |
| US-20260092059-A1 | Broad Spectrum Antiviral Compositions and Methods | EVRYS BIO, LLC (US) | 2026-04-02 | — | — | US | claimed |
| US-12582148-B2 | Compositions and methods for improving quality of life in patients with autism spectrum disorder | FLAASK, LLC (US) | 2026-03-24 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| WO-1995012313-A1 | VIRUS ASSOCIATED MULTIPLE SCLEROSIS: TREATMENTS, PREVENTION AND DIAGNOSIS THEREOF | PATHOGENESIS CORPORATION (US) | 1995-05-11 | — | — | WO | claimed |
| WO-1994026273-A1 | ACYCLOVIR DERIVATIVES FOR TOPICAL USE | HOSTETLER KARL Y (US) | 1994-11-24 | — | — | WO | claimed |
| US-5159067-A | 5'-Diphosphohexose nucleoside pharmaceutical compositions | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC. (US) | 1992-10-27 | — | — | US | claimed |
| EP-0283065-B1 | COMBINATIONS OF FU AND BVU AS ANTI-ADENOCARCINOMA AGENTS | Stichting REGA V.Z.W. (BE) | 1991-05-29 | — | — | EP | claimed |
| US-4988678-A | Fluorouracil and tetrahydrofuryl-5-fluorouracil as an antitumor agent and bromovinyluracil and 5-(2-bromovinyl-2'-deoxyuridine | STICHTING REGA VZW (BE) | 1991-01-29 | — | — | US | claimed |
| US-4894365-A | 5-FLUOROURACIL AND BROMOVINYLURACIL | STICHTING REGA VZW (BE) | 1990-01-16 | — | — | US | claimed |
| EP-0143987-B1 | THERAPEUTIC COMPOSITIONS ENDOWED WITH ANTIVIRAL ACTIVITY | Stendardi, Anna Gioia (IT) | 1989-02-22 | — | — | EP | claimed |
| EP-0143987-A1 | Therapeutic compositions endowed with antiviral activity | Stendardi, Anna Gioia (IT) | 1985-06-12 | — | — | EP | claimed |
| EP-0090837-A1 | METHOD AND COMPOSITION FOR TREATING A PATIENT SUFFERING FROM INTERFERONSUSCEPTIBLE DISORDER | BERG, Kurt Frimann (DK) | 1983-10-12 | — | — | EP | claimed |
| WO-1983001198-A1 | METHOD AND COMPOSITION FOR TREATING A PATIENT SUFFERING FROM INTERFERON-SUSCEPTIBLE DISORDER | BERG, KURT, FRIMANN | 1983-04-14 | — | — | WO | claimed |